Saturday, November 27

▷ Patients with non-small cell lung cancer with brain metastases: New data on …

29.10.2021 – 20:36

European Cancer Organisation

BRUSSELS, Feb. 23 / PRNewswire /

Non-small cell lung cancer (NSCLC) accounts for 85 percent of lung cancer cases, with 40 percent of patients occurring at an advanced stage, including those with metastases. [1]

Forty percent of healthcare providers (oncologists and pulmonologists) surveyed in five European countries and the United States feel less good (i.e., somewhat, fairly bad, or very bad) about caring for patients with non-small cell lung cancer (NSCLC) armed with brain metastases, according to a new survey by Ipsos MORI in collaboration with the European Cancer Organization (ECO). The report should be on the ECO Community 365 Roundtable Meeting on Metastatic Cancer will be presented on October 27th.

“The results suggest what the lung cancer community has unfortunately known for too long,” said Dr. Matti Aapro, President of the European Cancer Organization. “As treatment options for non-small cell lung cancer (NSCLC) patients expand, it is critical that we promptly address the complex challenges of coordinating care for patients who also have brain metastases. The same thing also applies to other cancers where valuable options are either ignored or not available. “

Despite recent advances, many people with non-small cell lung cancer (NSCLC) have a poor prognosis, as the five-year survival rate decreases significantly as the disease progresses. NSCLC patients with brain metastases have special care needs that are significantly more complex for patients, nurses, and healthcare providers.

“Treating patients with brain metastases is much more complex than treating patients without brain metastases, and their need for support is significant,” said Kathy Oliver, Co-Chair of the ECO Patient Advisory Board and Chair and Founding Co-Director of the International Brain Cancer Alliance (IBTA).

“It is imperative that we work together in advocacy, clinic and policy to ensure that healthcare providers and people living with brain metastases have access to quality treatment and multidisciplinary care. We need to focus more on how we do together to better meet the enormous unmet need in the difficult double diagnosis of advanced NSCLC and brain metastases, “added Dr. Anne-Marie Baird, Member of the ECO Patient Advisory Board and President of Lung Cancer Europe.

The results of the survey, carried out by Ipsos MORI in September 2021, of 350 oncologists and pulmonologists from the United States, the European Union (four countries in the EU: Germany, France, Italy, Spain) and the UK survey highlighted the complexities of NSCLC and the problems that healthcare providers and their patients face:

  • 40% of the health care professionals surveyed felt less well equipped (somewhat / fairly and very badly) for treating NSCLC patients with brain metastases, and 39% said it was difficult to get biomarker tests done in a timely manner Find.
  • Three out of four healthcare professionals surveyed agreed that coordinating medical care is more challenging for NSCLC patients with brain metastases than for NSCLC patients without brain metastases.
  • Two out of five doctors (41%) find it difficult to be open and honest with patients when they are asked difficult questions (e.g. prognosis, likelihood of relapse, etc.).
  • Half of healthcare professionals (51%) report that providing emotional and / or moral support to the patient, caregiver and family is challenging.
  • In addition to treatment, a survival plan is considered important for the patient, for example 30% of the representatives of the health care sector surveyed, but before psychological support (e.g. access to psychotherapists / psychologists / counseling) for the patients (55%), the practical support for the caregivers (46%) and the emotional support for the caregivers (43%).
  • Fifty-two percent of health care professionals surveyed said they lack the time to talk to patients or caregivers about their condition, and 44% admit that a lack of quality information is treating these patients / inside made more difficult.

Some of the health care professionals surveyed (24%) also said they were dissatisfied with the amount of information available to patients and caregivers, which is a critical area where improvements can be made to meet unmet needs to meet the needs of patients. According to the HCPS survey, patients and their carers would like to know more about their condition:

  • Life expectancy (64%)
  • Treatment of side effects (52%)
  • Radiation therapies (52%)
  • Palliative medicine and end-of-life care (52%)
  • Treatment benefits and risks for informed decision-making (47%)
  • Systemic medical treatments available (46%)
  • For more information on the survey, please click here.

Notes to the editors:

1. Information on the European Cancer Organization

The European Cancer Organization is the largest multi-professional cancer organization in Europe. It aims to reduce the burden of cancer, improve outcomes and improve the quality of care for cancer patients through multidisciplinary and multi-professionalism. As a non-profit association of member organizations working in the field of cancer at European level, the European Cancer Organization brings together oncology professionals and patients to make political decisions, advocate positive change and advocate for the European cancer community. You can find more information here.

2. Information about the survey

The political requirements for metastatic cancer were comparatively neglected at the European and national level. The European Cancer Organization is pleased to work with many organizations within its membership and networks to address and clarify the challenges and opportunities for better care for patients with metastatic cancer. In preparation for the Community 365 Roundtable Meeting on Metastatic Cancer, Ipsos MORI carried out an online survey between 3 and 27 September 2021 among 350 participants who had decided to take part in the survey (oncologists or specialists for respiratory diseases who have been directly involved in the treatment of at least five NSCLC patients in the past six months, at least one of whom has a brain metastasis and who have been practicing for 3-30 years in the United States (100) , Great Britain (50), Germany (50), France (50), Spain (50) and Italy (50).

Ipsos not only presented the results for each of the six countries individually, but also produced a total based on country averages. In this case, the results from each country have the same weight and not the actual population proportions of the six countries. You can find the results of the survey here.

This survey was funded by Regeneron and Sanofi to identify the unmet needs of NSCLC patients with brain metastases.

3. Informationen zum Community 365 Roundtable Meeting on Metastatic Cancer

This meeting will take place on Wednesday, October 27th from 10: 00-12: 30 CEST and will bring together key decision-makers, politicians, oncology experts and patient advocates to implement the European plan to fight cancer and the Cancer Mission and other EU policy developments related to metastatic cancer.

The round table will provide the opportunity to present the results of a survey of health care professionals in Europe and the United States focusing on the unmet needs of non-small cell lung cancer (NSCLC) patients with metastatic brain disease. In addition, the most important political requirements for improving the quality of care for patients with metastatic cancer are examined and technological and practical developments are examined using the examples of breast, prostate and lung cancer. You can find more information here.

4.Non-small cell lung cancer (NSCLC) information

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all lung cancer diagnoses

Lung cancer has the lowest 5-year survival rate of the other most common cancers: only 18% versus 99% for prostate cancer, 89% for breast cancer and 65% for colon cancer. 3

Brain metastases occur in some of the NSCLC patients. In a 2018 study, brain metastases were observed in 10.4% of over 450,000 patients with NSCLC

1 Ali, A., Griffin, J., Arnold, A. and Ellis, P, 2021. Survival of Patients with Non-Small Cell Lung Cancer after Diagnoses of Brain Metastases
2 Ali, A., Griffin, J., Arnold, A. and Ellis, P, 2021. Survival of Patients with Non-Small Cell Lung Cancer after Diagnoses of Brain Metastases
3 Lung Cancer Europe. 
4 Waqar et al, 2018, Non-small-cell Lung Cancer With Brain Metastasis at Presentation

Press contacts

Agnese Abolina, Communication and Community Manager, European Cancer Organization [email protected]

Original content by: European Cancer Organization, transmitted by news aktuell

Leave a Reply

Your email address will not be published. Required fields are marked *